Your browser doesn't support javascript.
loading
Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam.
Nukaga, Michiyoshi; Papp-Wallace, Krisztina M; Hoshino, Tyuji; Lefurgy, Scott T; Bethel, Christopher R; Barnes, Melissa D; Zeiser, Elise T; Johnson, J Kristie; Bonomo, Robert A.
Afiliación
  • Nukaga M; Department of Pharmaceutical Sciences, Josai International University, Togane City, Chiba, Japan.
  • Papp-Wallace KM; Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA krisztina.papp@va.gov robert.bonomo@va.gov.
  • Hoshino T; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
  • Lefurgy ST; Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
  • Bethel CR; Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, Japan.
  • Barnes MD; Department of Chemistry, Hofstra University, Hempstead, New York, USA.
  • Zeiser ET; Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
  • Johnson JK; Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
  • Bonomo RA; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Article en En | MEDLINE | ID: mdl-29439972
ABSTRACT
Ceftazidime-avibactam is a "second-generation" ß-lactam-ß-lactamase inhibitor combination that is effective against Enterobacteriaceae expressing class A extended-spectrum ß-lactamases, class A carbapenemases, and/or class C cephalosporinases. Knowledge of the interactions of avibactam, a diazabicyclooctane with different ß-lactamases, is required to anticipate future resistance threats. FOX family ß-lactamases possess unique hydrolytic properties with a broadened substrate profile to include cephamycins, partly as a result of an isoleucine at position 346, instead of the conserved asparagine found in most AmpCs. Interestingly, a single amino acid substitution at N346 in the Citrobacter AmpC is implicated in resistance to the aztreonam-avibactam combination. In order to understand how diverse active-site topologies affect avibactam inhibition, we tested a panel of clinical Enterobacteriaceae isolates producing blaFOX using ceftazidime-avibactam, determined the biochemical parameters for inhibition using the FOX-4 variant, and probed the atomic structure of avibactam with FOX-4. Avibactam restored susceptibility to ceftazidime for most isolates producing blaFOX; two isolates, one expressing blaFOX-4 and the other producing blaFOX-5, displayed an MIC of 16 µg/ml for the combination. FOX-4 possessed a k2/K value of 1,800 ± 100 M-1 · s-1 and an off rate (koff) of 0.0013 ± 0.0003 s-1 Mass spectrometry showed that the FOX-4-avibactam complex did not undergo chemical modification for 24 h. Analysis of the crystal structure of FOX-4 with avibactam at a 1.5-Å resolution revealed a unique characteristic of this AmpC ß-lactamase. Unlike in the Pseudomonas-derived cephalosporinase 1 (PDC-1)-avibactam crystal structure, interactions (e.g., hydrogen bonding) between avibactam and position I346 in FOX-4 are not evident. Furthermore, another residue is not observed to be close enough to compensate for the loss of these critical hydrogen-bonding interactions. This observation supports findings from the inhibition analysis of FOX-4; FOX-4 possessed the highest Kd (dissociation constant) value (1,600 nM) for avibactam compared to other AmpCs (7 to 660 nM). Medicinal chemists must consider the properties of extended-spectrum AmpCs, such as the FOX ß-lactamases, for the design of future diazabicyclooctanes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Bacterianas / Beta-Lactamasas / Compuestos de Azabiciclo Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Bacterianas / Beta-Lactamasas / Compuestos de Azabiciclo Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Japón